VACCINES FORMED BY VIRUS AND ANTIGEN CONJUGATION
Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).
1 . A method of conjugating at least one antigen to a virus particle, comprising mixing the virus particle and the at least one antigen to form a conjugate mixture, wherein the at least one antigen comprises a fusion peptide formed of a first peptide which is a subunit of a protein, and a second peptide which is a fragment crystallizable (Fc) region of an antibody capable of binding to a Fc receptor, wherein when the virus particle releases the at least one antigen in a mammalian subject having cells that include one or more ACE-2 receptors, the at least one antigen binds to the one or more ACE-2 receptors.
2 . The method of claim 1 , further comprising an activating step that occurs before mixing the virus particle and the at least one antigen, wherein the activating step comprises exposing the virus particle to a pH of about 5.5 or less.
3 . The method of claim 1 , wherein the first peptide is a receptor binding domain of a spike protein of a coronavirus, and the receptor binding domain comprises contact residues located in a range from about position 289 to about position 662 of the subunit.
4 . The method of claim 3 , wherein the contact residues are located in a range from about position 301 to about position 662 of the S-1 subunit.
5 . The method of claim 2 , wherein the first peptide is a receptor binding domain of a spike protein of a coronavirus, and the receptor binding domain comprises contact residues located in a range from about position 289 to about position 662 of the subunit.
6 . The method of claim 5 , wherein the contact residues are located in a range from about position 301 to about position 662 of the S-1 subunit.
7 . The method of claim 1 , wherein the virus particle is a virus.
8 . The method of claim 7 , wherein the virus is a tobacco mosaic virus.
9 . The method of claim 1 , wherein the first peptide contains an amino acid sequence as set forth in SEQ ID NO: 2 or 8.
10 . The method of claim 1 , wherein the second peptide contains an amino acid sequence as set forth in SEQ ID NO: 4.
11 . The method of claim 1 , further comprising expressing an amino acid sequence comprising a third peptide wherein the third peptide is a hinge portion linking the first peptide and the second peptide.
12 . The method of claim 11 , wherein the third peptide contains an amino acid sequence as set forth in SEQ ID NO: 3.